Short Interest in Femasys Inc. (NASDAQ:FEMY) Drops By 7.1%

Femasys Inc. (NASDAQ:FEMY) was the recipient of a large drop in short interest in November. As of November 15th, there was short interest totalling 489,100 shares, a drop of 7.1% from the October 31st total of 526,700 shares. Based on an average trading volume of 172,600 shares, the short-interest ratio is currently 2.8 days. Currently, 2.3% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on FEMY shares. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Femasys in a research report on Tuesday. Chardan Capital cut their target price on Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Femasys Price Performance

Shares of FEMY traded down $0.02 on Tuesday, reaching $1.08. 123,052 shares of the company’s stock traded hands, compared to its average volume of 325,954. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The stock’s 50 day simple moving average is $1.14 and its two-hundred day simple moving average is $1.12. Femasys has a 52-week low of $0.73 and a 52-week high of $2.40.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The company had revenue of $0.55 million for the quarter, compared to analysts’ expectations of $0.40 million. As a group, equities analysts expect that Femasys will post -0.84 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in FEMY. CM Management LLC raised its position in shares of Femasys by 6.3% in the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after buying an additional 25,000 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after acquiring an additional 17,473 shares in the last quarter. XTX Topco Ltd raised its position in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the period. Finally, Aljian Capital Management LLC bought a new position in shares of Femasys during the third quarter valued at about $27,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.